Adam Maeder

Stock Analyst at Piper Sandler

(1.54)
# 1424
Out of 5,328 analysts
136
Total ratings
51.72%
Success rate
8.64%
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
RMD ResMed
Maintains: Neutral
260 248
238.29 4.07% 3 Apr 24, 2025
EW Edwards Lifesciences
Upgrades: Overweight
73 80
75.5 5.96% 14 Apr 24, 2025
ISRG Intuitive Surgical
Maintains: Overweight
670 575
522.32 10.09% 19 Apr 23, 2025
ABT Abbott Laboratories
Reiterates: Overweight
133 145
130.75 10.9% 3 Apr 17, 2025
RXST RxSight
Initiates Coverage On: Neutral
18
14.79 21.7% 1 Apr 15, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
11 9
8 6.25% 7 Mar 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
260 233
159.13 46.42% 14 Feb 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
6 6
n/a n/a 16 Feb 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
52 80
n/a n/a 7 Jan 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
5 5
2.62 71.76% 3 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
20 21
11.78 78.27% 2 May 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
18 20
n/a n/a 6 May 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
290 360
n/a n/a 10 Apr 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
7 8
4.4 81.82% 1 Mar 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
15 20
6.05 230.58% 8 Mar 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
75 71
n/a n/a 8 Jan 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
25 30
14.14 112.16% 2 May 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
6 5
2.02 147.52% 2 Mar 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
10 18
1.86 867.74% 2 Jan 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
104 99
36.88 168.44% 3 May 5, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 11
n/a n/a 5 Jun 14, 2021